Trial Profile
Assessment of the efficacy of lanreotide autogel in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegaly
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2005
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Octreotide
- Indications Hypertension; Left ventricular hypertrophy; Sleep apnoea syndrome
- Focus Therapeutic Use
- 15 Jul 2005 New trial record.